Nirogacestat

Generic Name: Nirogacestat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₁F_₂N_₅O

CAS Number: 1290543-63-3

Unique Ingredient Identifier: QZ62892OFJ

Background: Nirogacestat has been used in trials studying the treatment of Breast Cancer, HIV Infection, Desmoid Tumors, Advanced Solid Tumors, and Aggressive Fibromatosis, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: GSK3174998
Drug: Feladilimab
Drug: Nirogacestat
Drug: Dostarlimab
Drug: Isatuximab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Pomalidomide

First Posted Date: 2019-10-15

Last Posted Date: 2025-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 209

Registration Number: NCT04126200

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy